Vulvar Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Vulvar Cancer - Pipeline Review, H1 2016', provides an overview of the Vulvar Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Vulvar Cancer - The report reviews pipeline therapeutics for Vulvar Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Vulvar Cancer therapeutics and enlists all their major and minor projects - The report assesses Vulvar Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Vulvar Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Vulvar Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Vulvar Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vulvar Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Vulvar Cancer - Overview 7 Pipeline Products for Vulvar Cancer - Comparative Analysis 8 Vulvar Cancer - Therapeutics under Development by Companies 9 Vulvar Cancer - Therapeutics under Investigation by Universities/Institutes 10 Vulvar Cancer - Pipeline Products Glance 11 Clinical Stage Products 11 Vulvar Cancer - Products under Development by Companies 12 Vulvar Cancer - Products under Investigation by Universities/Institutes 13 Vulvar Cancer - Companies Involved in Therapeutics Development 14 ISA Pharmaceuticals B.V. 14 Ono Pharmaceutical Co., Ltd. 15 Oryx GmbH & Co. KG 16 PDS Biotechnology Corporation 17 Vulvar Cancer - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ISA-101 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 nivolumab - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 omiganan pentahydrochloride - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 PDS-0101A - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vicoryx - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Vulvar Cancer - Recent Pipeline Updates 43 Vulvar Cancer - Dormant Projects 69 Vulvar Cancer - Product Development Milestones 70 Featured News & Press Releases 70 Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 70 Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 70 Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 70 Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for Vulvar Cancer, H1 2016 7 Number of Products under Development for Vulvar Cancer - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Vulvar Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 14 Vulvar Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 15 Vulvar Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 16 Vulvar Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Vulvar Cancer Therapeutics - Recent Pipeline Updates, H1 2016 43 Vulvar Cancer - Dormant Projects, H1 2016 69
List of Figures
Number of Products under Development for Vulvar Cancer, H1 2016 7 Number of Products under Development for Vulvar Cancer - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 19 Number of Products by Stage and Targets, H1 2016 19 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 25
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from mainRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.